유방암의 호르몬 치료
Hormone Treatment for Breast Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hormone receptor-positive breast cancer accounts for 60-70% of all breast cancers and has a better prognosis than human epidermal growth factor receptor-2 (HER2)-positive or triple-negative breast cancer. Hormone treatment for breast cancer is an important treatment method that is effective and has few side effects for hormone receptor-positive breast cancer. Hormone therapy is performed as adjuvant therapy in early breast cancer and as palliative therapy in metastatic breast cancer. In the past decade, molecularly targeted agents against intracellular targets such as mammalian target of rapamycin (everolimus), cyclin-dependent kinase 4 and 6 (palbociclib, ribociclib, abemaciclib), and phosphatidylinositol 3-kinase (alpelisib) has offered patients effective therapeutic options, and combination of hormone treatment with the molecular agents have continued to improve the outcome of breast cancer.
Abstract
Hormone receptor-positive breast cancer accounts for 60-70% of all breast cancers and has a better prognosis than human epidermal growth factor receptor-2 (HER2)-positive or triple-negative breast cancer. Hormone treatment for breast cancer is an important treatment method that is effective and has few side effects for hormone receptor-positive breast cancer. Hormone therapy is performed as adjuvant therapy in early breast cancer and as palliative therapy in metastatic breast cancer. In the past decade, molecularly targeted agents against intracellular targets such as mammalian target of rapamycin (everolimus), cyclin-dependent kinase 4 and 6 (palbociclib, ribociclib, abemaciclib), and phosphatidylinositol 3-kinase (alpelisib) has offered patients effective therapeutic options, and combination of hormone treatment with the molecular agents have continued to improve the outcome of breast cancer.
참고문헌 (29)
- 강미주, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020", Cancer Research and Treatment, 55(2), pp.385~399 (2023), 대한암학회[DOI]
- Prat A, "Clinical implications of the intrinsic molecular subtypes of breast cancer", Breast, 24(Suppl 2), pp.S26~S35 (2015)
- Burstein HJ, "Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer : ASCO clinical practice guideline focused update", J Clin Oncol, 37, pp.423~438 (2019)
- Burstein HJ, "Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer : ASCO guideline update", J Clin Oncol, 39, pp.3959~3977 (2021)
- Howell SJ, "The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer", Best Pract Res Clin Endocrinol Metab, 18, pp.47~66 (2004)
- Downton T, "Oral selective estrogen receptor degraders(SERDs)in breast cancer : advances, challenges, and current status", Drug Des Devel Ther, 16, pp.2933~2948 (2022)
- Smith IE, "Aromatase inhibitors in breast cancer", N Engl J Med, 348, pp.2431~2442 (2003)
- Francis PA, "Adjuvant ovarian suppression in premenopausal breast cancer", N Engl J Med, 372, pp.436~446 (2015)
- Early Breast Cancer Trialists' Collaborative Group(EBCTCG), "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials", Lancet, 365, pp.1687~1717 (2005)
- Arimidex, Tamoxifen, Alone or in Combination (ATAC)Trialists' Group, "Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer : 100-month analysis of the ATAC trial", Lancet Oncol, 9, pp.45~53 (2008)
- Breast International Group(BIG)1-98 Collaborative Group, "A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer", N Engl J Med, 353, pp.2747~2757 (2005)
- Boccardo F, "Switching to anastrozole versus continued tamoxifen treatment of early breast cancer : preliminary results of the Italian Tamoxifen Anastrozole Trial", J Clin Oncol, 23, pp.5138~5147 (2005)
- Coombes RC, "Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment(intergroup exemestane study) : a randomised controlled trial", Lancet, 369, pp.559~570 (2007)
- Jin H, "Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA. 17 trial : analyses adjusting for treatment crossover", J Clin Oncol, 30, pp.718~721 (2012)
- Pagani O, "Adjuvant exemestane with ovarian suppression in premenopausal breast cancer", N Engl J Med, 371, pp.107~118 (2014)
- Francis PA, "Tailoring adjuvant endocrine therapy for premenopausal breast cancer", N Engl J Med, 379, pp.122~137 (2018)
- Davies C, "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer : ATLAS, a randomised trial", Lancet, 381, pp.805~816 (2013)
- Johnston SRD, "Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer(monarchE) : results from a preplanned interim analysis of a randomised, open-label, phase 3 trial", Lancet Oncol, 24, pp.77~90 (2023)
- Finn RS, "Palbociclib and letrozole in advanced breast cancer", N Engl J Med, 375, pp.1925~1936 (2016)
- Goetz MP, "MONARCH 3 : abemaciclib as initial therapy for advanced breast cancer", J Clin Oncol, 35, pp.3638~3646 (2017)
- Hortobagyi GN, "Overall survival with ribociclib plus letrozole in advanced breast cancer", N Engl J Med, 386, pp.942~950 (2022)
- Im SA, "Overall survival with ribociclib plus endocrine therapy in breast cancer", N Engl J Med, 381, pp.307~316 (2019)
- Turner NC, "Overall survival with palbociclib and fulvestrant in advanced breast cancer", N Engl J Med, 379, pp.1926~1936 (2018)
- Slamon DJ, "Overall survival with ribociclib plus fulvestrant in advanced breast cancer", N Engl J Med, 382, pp.514~524 (2020)
- Sledge GW Jr, "The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2 : a randomized clinical trial", JAMA Oncol, 6, pp.116~124 (2020)
- Brett JO, "ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer", Breast Cancer Res, 23, pp.85~ (2021)
- Bidard FC, "Elacestrant(oral selective estrogen receptor degrader)versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : results from the randomized phase III EMERALD trial", J Clin Oncol, 40, pp.3246~3256 (2022)
- Baselga J, "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer", N Engl J Med, 366, pp.520~529 (2012)
- André F, "Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer", N Engl J Med, 380, pp.1929~1940 (2019)